Womb Cancer Screening
New Noninvasive Urine and Vaginal Test Could Help Detect Womb Cancer Early
Anonymous
Key Points
1
The study was conducted across seven hospitals in north-west England. Of the 1,864 participants, 99—about 5%—were diagnosed with womb cancer, and the test identified 80 of those 99 cases while correctly returning a negative result for 93% of women without womb cancer.
2
Researchers said the test should not yet be used to rule out cancer by itself. Instead, it could fast-track women at highest risk for urgent investigation while allowing lower-risk patients to undergo repeat sampling or full assessment if bleeding continues.
3
The study’s strong performance among Black women is particularly significant because Black women in the UK are twice as likely as White women to die from womb cancer; separate research cited by the Manchester team found that existing tests are poorly calibrated for Black patients, contributing to disparities in diagnosis and outcomes.
4
The samples were assessed by highly trained specialist cytologists who knew the laboratory procedures, so researchers cautioned that the test’s accuracy may not be reproducible in other clinical settings; its use in primary care and community locations would require additional validation.
Researchers at the University of Manchester have developed a simple test that analyzes urine and vaginal fluid to detect womb cancer in women with postmenopausal bleeding. FemTech World reports the test identified 80 of 99 womb cancers in a study of 1,864 women, while correctly ruling out cancer in 93% of women without it. The breakthrough could spare thousands of patients from painful biopsies and invasive procedures.
The test showed particularly strong results for Black women, who are twice as likely as White women in the UK to die from womb cancer. The Independent notes the findings could help reduce healthcare disparities and improve diagnosis across different populations. However, researchers warn the test is not yet accurate enough to rule out cancer on its own.
A Test That Works on Body Fluids, Not Tissue Biopsies
The new test analyzes cells found naturally in urine and vaginal fluid. Upday explains that current diagnosis methods require invasive procedures like biopsies or hysteroscopies. Only 5% to 10% of women referred for postmenopausal bleeding actually have cancer, meaning most undergo unnecessary invasive tests. This noninvasive approach could change that.
In the seven-hospital study across northwest England, the test identified 80% of womb cancers. It had a 98.8% negative predictive value, meaning when it came back negative, cancer was very unlikely. The test also detected most high-grade and advanced tumors, the most dangerous types.
Why Results in Black Women Matter for Health Equity
Black women face a stark health crisis: they die from womb cancer at twice the rate of White women in the UK. Mirror reports that existing diagnostic tests are poorly calibrated for Black patients, contributing to these deadly disparities. The new test performed equally well across racial groups, offering hope for equitable care.
All womb cancers among Black participants in the study were detected by the test. This matters because it suggests the test could help close a critical gap in cancer diagnosis. Better detection in underserved communities could prevent thousands of deaths over time.
Cautious Next Steps Before Widespread Use
Researchers stress that this test is not ready to rule out cancer on its own. Instead, it could fast-track high-risk women for urgent investigation while allowing lower-risk patients to avoid immediate biopsies. Women with bleeding would still need follow-up care if symptoms continue.
The test was performed by highly trained specialist cytologists in laboratory settings. FemTech World notes that its accuracy may not hold up in primary care or community clinics without additional validation. Further research is needed before the test moves beyond specialist hospitals into routine medical practice.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
20
Reach
32
Topics
A
AnonymousAuthor
